Skip to main
UTHR

United Therapeutics (UTHR) Stock Forecast & Price Target

United Therapeutics (UTHR) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

United Therapeutics is poised for growth and success with its drug therapies that target the prostacyclin pathway and its dominant position in the PAH market. The positive TETON-1 and TETON-2 data support the use of Tyvaso as monotherapy or in combination therapy for IPF, while the company's disciplined operating expenses and promising pipeline add to its strong outlook for the future. With a diverse portfolio of commercial and potential products, United Therapeutics is well-positioned to continue its success and deliver positive results for both patients and investors.

Bears say

United Therapeutics is heavily reliant on sales of Tyvaso DPI and its other treatments for PAH, with limited diversification in terms of revenue sources. The success of its TETON-1 and TETON-2 trials may lead to wider adoption of Tyvaso as a standard of care, but concerns around cough, sore throat, and adherence to the inhaled regimen may limit its usage. The company's future potential depends on the success and regulatory support of its pipeline products, including nebulized Tyvaso and TRESMI, which may face challenges in the competitive and highly regulated market for PAH treatments.

United Therapeutics (UTHR) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About United Therapeutics (UTHR) Forecast

Analysts have given United Therapeutics (UTHR) a Buy based on their latest research and market trends.

According to 11 analysts, United Therapeutics (UTHR) has a Buy consensus rating as of Aug 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $643.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $643.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

United Therapeutics (UTHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.